

**AMENDMENT**

In the Claims:

Please amend claims 51-58 so that after the amendments, the following claims are pending in this application:

- 
51. (Amended) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a mammalian IL-B30/p40 complex, said complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of human or murine origin, wherein said antibody binds an epitope presented by the IL-B30/p40 complex, but exhibits less than 10% crossreactivity with any epitope presented by either IL-B30 alone or p40 alone.
52. (Amended) The binding compound of claim 51, wherein said binding compound is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab' fragment, or F(ab')<sub>2</sub> fragment.
53. (Amended) The binding compound of claim 51, wherein said binding compound is a neutralizing antibody.
54. (Amended) A composition comprising the binding compound of claim 51 and a pharmaceutically acceptable carrier or diluent.
55. (Amended) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a fusion protein comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of human or murine origin, wherein said antibody binds an epitope presented by said fusion protein, but exhibits less than 10% crossreactivity with any epitope presented solely by either IL-B30 alone or p40 alone.

56. (Amended) The binding compound of claim 55, wherein said binding compound is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab' fragment, or F(ab')<sub>2</sub> fragment.

57. (Amended) The binding compound of claim 55, wherein said binding compound is a neutralizing antibody.

*E!*  
*cancel* 58. (Amended) A composition comprising the binding compound of claim 55 and a pharmaceutically acceptable carrier or diluent.

---

59. A method of producing an immunocomplex of antigen:binding compound, comprising contacting a mammalian p40/IL-B30 complex with a binding compound of claim 51, thereby allowing said immunocomplex to form.

60. The method of claim 59, wherein said binding compound is admixed with a pharmaceutically acceptable carrier or diluent.

61. A method of producing an immunocomplex of antigen:binding compound, comprising contacting a mammalian p40/IL-B30 complex with a binding compound of claim 55, thereby allowing said immunocomplex to form.

62. The method of claim 61, wherein said binding compound is admixed with a pharmaceutically acceptable carrier or diluent.

Pursuant to 37 C.F.R. §1.121(c)(1)(ii), a marked-up copy of the amended claims is attached herewith on separate pages.